Barasertib-HQPA

Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells[1].

Product Specifications

CAS Number

[722544-51-6]

Product Name Alternative

AZD2811; INH-34; AZD1152-HQPA

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Aurora Kinase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AZD1152-HQPA.html

Purity

99.33

Solubility

DMSO : ≥ 22 mg/mL

Smiles

O=C(CC1=NNC(NC2=C3C=CC(OCCCN(CCO)CC)=CC3=NC=N2)=C1)NC4=CC=CC(F)=C4

Molecular Formula

C26H30FN7O3

Molecular Weight

507.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007 Jun 15;13 (12) :3682-8.|[2]Yang, Jing., et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep 15;110 (6) :2034-40.|[3]Zekri A, et al. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Tumour Biol. 2015 Feb;36 (2) :623-32.|[4]Oke A, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009 May 15;69 (10) :4150-8.